author-photo

Avie-Lee Tillotson

University of Leeds

4

Papers

22

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Bortezomib, vorinostat and dexamethasone combination therapy in relapsed myeloma: results of the phase 2 MUK four trial WQZa

2020 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

2016 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

2015 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (14)
Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)